Trials / Completed
CompletedNCT00187525
A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- University of California, San Francisco · Academic / Other
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a 52-week, multicenter, open label trial of memantine (Namenda) for frontotemporal lobar degeneration (FTLD). The goal is to determine the safety and tolerability of this FDA-approved medication for Alzheimer's Disease in patients with FTLD. Secondary outcome measures include cognitive batteries, rating scales for activities of daily living and neuropsychiatric symptoms. All patients receive the FDA-approved dose of this medication for Alzheimer's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Memantine |
Timeline
- Start date
- 2004-05-01
- Primary completion
- 2005-10-01
- Completion
- 2006-10-01
- First posted
- 2005-09-16
- Last updated
- 2012-11-12
Source: ClinicalTrials.gov record NCT00187525. Inclusion in this directory is not an endorsement.